Applications of Nuclear Magnetic Resonance and Mass Spectrometry to Anticancer Drug Discovery

Novel Anticancer Agents

Volumn , Issue , 2006, Pages 107-190

  Powers, Robert ^a   Siegel, Marshall M ^b  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^b WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84871282959     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088561-9/50006-5     Document Type: Chapter

References (424)

1. Gubernator K, Boehm HJ Examples of active areas of structure based-design. Methods Princ. Med. Chem. 1998, 6:15-36.
2. Kubinyi H Structure-based design of enzyme inhibitors and receptor ligands. Curr. Opin. Drug Disc. Dev. 1998, 1:4-15.
3. Li J, Murray CW, Waszkowycz B, Young SC Targeted molecular diversity in drug discovery: Integration of structure-based design and combinatorial chemistry. Drug Disc. Today 1998, 3:105-112.
4. Gane PJ, Dean PM Recent advances in structure-based rational drug design. Curr. Opin. Struct. Biol. 2000, 10:401-404.
5. Morris PE, Omura GA Inhibitors of the enzyme purine nucleoside phosphorylase as potential therapy for psoriasis. Curr. Pharm. Des. 2000, 6:943-959.
6. Maignan S, Mikol V The use of 3D structural data in the design of specific Factor Xa inhibitors. Curr. Top. Med. Chem. 2001, 1:161-174.
7. Craik DJ, Scanlon MJ Pharmaceutical applications of NMR. Annu. Rep. NMR Spectrosc. 2000, 42:115-174.
8. Colacino JM, Staschke KA, Laver WG Approaches and strategies for the treatment of influenza virus infections. Antiviral Chem. Chemother. 1999, 10:155-185.
9. Mihelich ED, Schevitz RW Structure-based design of a new class of anti-inflammatory drugs: secretory phospholipase A2 inhibitors, SPI. Biochim. Biophys. Acta 1999, 1441:223-228.
10. Sintchak MD, Nimmesgern E The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology 2000, 47:163-184.
11. Sem DS, Pellecchia M NMR in the acceleration of drug discovery. Curr. Opin. Drug Disc. Dev. 2001, 4:479-492.
12. Roberts GCK Applications of NMR in drug discovery. Drug Disc. Today 2000, 5:230-240.
13. Roberts GCK NMR spectroscopy in structure-based drug design. Curr. Opin. Biotechnol. 1999, 10:42-47.
14. Prestegard JH, Valafar H, Glushka J, Tian F Nuclear magnetic resonance in the era of structural genomics. Biochemistry 2001, 40:8677-8685.
15. Craik DJ, Nielsen KJ, Higgins KA Pharmaceutical applications of NMR. Annu. Rep. NMR Spectrosc. 1996, 32:143-213.
16. Feeney J NMR studies of protein-ligand and protein-protein interactions involving proteins of therapeutic interest. NATO ASI Ser., Ser C 1999, 526:281-300.
17. Dunayevskiy YM, Lai J-J, Quinn C, Talley F, Vouros P Mass spectrometric identification of ligands selected from combinatorial libraries using gel filtration. Rapid Commun. Mass Spectrom. 1997, 11:1178-1184.
18. Siegel MM, Tabei K, Bebernitz GA, Baum EZ Rapid methods for screening low molecular mass compounds non-covalently bound to proteins using size exclusion and mass spectrometry applied to inhibitors of human cytomegalovirus protease. J. Mass Spectrum 1998, 33:264-273.
19. Siegel MM Early discovery drug screening using mass spectrometry. Curr. Top. Med. Chem. 2002, 2:13-33.
20. Armstrong JW A review of high-throughput screening approaches for drug discovery. Am. Biotechnol. Lab. 1999, 17:26-28.
21. Gonzalez JE, Negulescu PA Intracellular detection assays for high-throughput screening. Curr. Opin. Biotechnol. 1998, 9:624-631.
22. Oldenburg KR Current and future trends in high throughput screening for drug discovery. Annu. Rep. Med. Chem. 1998, 33:301-311.
23. Fernandes PB Technological advances in high-throughput screening. Curr. Opin. Chem. Biol. 1998, 2:597-603.
24. Kenny BA, Bushfield M, Parry-Smith DJ, Fogarty S, Treherne JM The application of high-throughput screening to novel lead discovery. Prog. Drug Res. 1998, 51:245-269.
25. Silverman L, Campbell R, Broach JR New assay technologies for high-throughput screening. Curr. Opin. Chem. Biol. 1998, 2:397-403.
26. Schreiber SL Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 2000, 287:1964-1969.
27. Nicolaou KC, Vourloumis D, Winssinger N, Baran PS The art and science of total synthesis at the dawn of the twenty-first century. Angew Chem. Int. Ed. 2000, 39:44-122.
28. Chakraborty TK Future directions in organic synthesis. J. Indian Chem. Soc. 2001, 78:211-223.
29. McGovern SL, Caselli E, Grigorieff N, Shoichet BK A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 2002, 45:1712-1722.
30. Oakley AJ, Wilce MCJ Macromolecular crystallography as a tool for investigating drug, enzyme and receptor interactions. Clin. Exp. Pharmacol. Physiol. 2000, 27:145-151.
31. Ferentz AE, Wagner G NMR spectroscopy: a multifaceted approach to macromolecular structure. Q. Rev. Biophys. 2000, 33:29-65.
32. Nogi T, Miki K Structural basis of bacterial photosynthetic reaction centers. J. Biochem. 2001, 130:319-329.
33. Tsukihara T, Aoyama H Membrane protein assemblies - towards atomic resolution analysis: commentary. Curr. Opin. Struct. Biol. 2000, 10:208-212.
34. Baleja JD Structure determination of membrane-associated proteins from nuclear magnetic resonance data. Anal. Biochem. 2001, 288:1-15.
35. Fernandez C, Hilty C, Bonjour S, Adeishvili K, Pervushin K, Wüthrich K Solution NMR studies of the integral membrane proteins OmpX and OmpA from Escherichia coli. FEBS Lett. 2001, 504:173-178.
36. Powell HR Molecular structure from X-ray diffraction. Annu. Rep. Prog. Chem., Section C: Physical Chemistry 2000, 96:139-175.
37. Smyth MS, Martin JHJ X-ray crystallography. Mol. Pathol. 2000, 53:8-14.
38. 15N multidimensional NMR to study the structure and dynamics of proteins. Annu. Rev. Biophys. Biomol. Struct. 1998, 27:357-406.
39. Kay LE, Gardner KH Solution NMR spectroscopy beyond 25 kDa. Curr. Opin. Struct. Biol. 1997, 7:722-731.
40. Clore GM, Gronenborn AM NMR structure determination of proteins and protein complexes larger than 20 kDa. Curr. Opin. Chem. Biol. 1998, 2:564-570.
41. Arrowsmith CH, Wu Y-S NMR of large (>25 kDa) proteins and protein complexes. Prog. Nucl. Magn. Reson. Spectrosc. 1998, 32:277-286.
42. Pervushin K Impact of transverse relaxation optimized spectroscopy (TROSY) on NMR as a technique in structural biology. Q. Rev. Biophys. 2000, 33:161-197.
43. Riek R, Pervushin K, Wüthrich K TROSY and CRINEPT: NMR with large molecular and supramolecular structures in solution. Trends Biochem. Sci. 2000, 25:462-468.
44. Wüthrich K NMR of Proteins and Nucleic Acids 1986, John Wiley & Sons, La Jolla, CA.
45. Otting G Experimental NMR techniques for studies of protein-ligand interactions. Curr. Opin. Struct. Biol. 1993, 3:760-768.
46. Whittle PJ, Blundell TL Protein structure-based drug design. Annu. Rev. Biophys. Biomol. Struct. 1994, 23:349-375.
47. Blundell TL Structure-based drug design. Nature 1996, 384:23-26. (Suppl).
48. Joseph-McCarthy D Computational approaches to structure-based ligand design. Pharmacol. Ther. 1999, 84:179-191.
49. Gmeiner WH NMR spectroscopy as a tool to investigate the structural basis of anticancer drugs. Curr. Med. Chem. 1998, 5:115-135.
50. Pindur U, Fischer G DNA complexing minor groove-binding ligands: Perspectives in antitumor and antimicrobial drug design. Curr. Med. Chem. 1996, 3:379-406.
51. Fowler CA, Tian F, Al-Hashimi HM, Prestegard JH Rapid determination of protein folds using residual dipolar couplings. J. Mol. Biol. 2000, 304:447-460.
52. Prestegard JH Orientational constraints of polypeptide folds: The role of NMR in structural genomics. Polym. Prepr. 2001, 42:60.
53. Tjandra N, Bax A Direct measurement of distances and angles in biomolecules by NMR in a dilute liquid crystalline medium. Science 1997, 278:1111-1114.
54. Moseley HNB, Montelione GT Automated analysis of NMR assignments and structures for proteins. Curr. Opin. Struct. Biol. 1999, 9:635-642.
55. Linge JP, O'Donoghue SI, Nilges M Automated assignment of ambiguous nuclear Overhauser effects with ARIA. Methods Enzymol. 2001, 339:71-90.
56. Greenfield NJ, Huang YJ, Palm T, et al. Solution NMR structure and folding dynamics of the n terminus of a rat non-muscle α-tropomyosin in an engineered chimeric protein. J. Mol. Biol. 2001, 312:833-847.
57. Xu Y, Jablonsky MJ, Jackson PL, Braun W, Krishna NR Automatic assignment of NOESY cross peaks and determination of the protein structure of a new world scorpion neurotoxin using NOAH/DIAMOD. J. Magn. Reson. 2001, 148:35-46.
58. Xu Y, Wu J, Gorenstein D, Braun W Automated 2D NOESY assignment and structure calculation of crambin(S22/I25) with the self-correcting distance geometry based NOAH/DIAMOD programs. J. Magn. Reson. 1999, 136:76-85.
59. Bowers PM, Strauss CEM, Baker D De novo protein structure determination using sparse NMR data. J. Biomo. NMR 2000, 18:311-318.
60. Rohl CA, Baker D De novo determination of protein backbone structure from residual dipolar couplings using rosetta. J. Am. Chem. Soc. 2002, 124:2723-2729.
61. Montelione GT, Zheng D, Huang YJ, Gunsalus KC, Szyperski T Protein NMR spectroscopy in structural genomics. Nat. Struct. Biol. 2000, 7:982-985.
62. Moore JM NMR techniques for characterization of ligand binding: Utility for lead generation and optimization in drug discovery. Biopolymers 1999, 51:221-243.
63. Moore JM NMR screening in drug discovery. Curr. Opin. Biotechnol. 1999, 10:54-58.
64. Peng JW, Lepre CA, Fejzo J, Abdul-Manan N, Moore JM Nuclear magnetic resonance-based approaches for lead generation in drug discovery. Methods Enzymol. 2001, 338:202-230.
65. Rossi C, Donati A, Sansoni MR Nuclear magnetic resonance as a tool for the identification of specific DNA-ligand interaction. Chem. Phys. Lett. 1992, 189:278-280.
66. Hajduk PJ, Olejniczak ET, Fesik SW One-dimensional relaxation- and diffusion-edited NMR methods for screening compounds that bind to macromolecules. J. Am. Chem. Soc. 1997, 119:12257-12261.
67. Lin M, Shapiro MJ, Wareing JR Diffusion-edited NMR-affinity NMR for direct observation of molecular interactions. J. Am. Chem. Soc. 1997, 119:5249-5250.
68. Lin M, Shapiro MJ, Wareing JR Screening mixtures by affinity NMR. J. Org. Chem. 1997, 62:8930-8931.
69. Waldeck AR, Kuchel PW, Lennon AJ, Chapman BE NMR diffusion measurements to characterize membrane transport and solute binding. Prog. Nucl. Magn. Reson. Spectrosc 1997, 30:39-68.
70. Shirakawa M, Lee SJ, Takimoto M, Matsuo H, Akutsu H, Kyogoku Y Interaction of the λ-cro repressor protein with operator DNA fragments monitored as to amide proton magnetic resonances. J. Mol. Struct. 1991, 242:355-366.
71. Ni F Recent developments in transferred NOE methods. Prog. Nucl. Magn. Reson. Spectrosc. 1994, 26:517-606.
72. Vogtherr M, Peters T Application of NMR based binding assays to identify key hydroxy groups for intermolecular recognition. J. Am. Chem. Soc. 2000, 122:6093-6099.
73. Mayer M, Meyer B Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew Chem. Int. Ed. 1999, 38:1784-1788.
74. Dalvit C, Pevarello P, Tato M, Veronesi M, Vulpetti A, Sundstrom M Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. J. Biomol. NMR 2000, 18:65-68.
75. Clore GM, Gronenborn AM Structures of larger proteins, protein-ligand and protein-DNA complexes by multidimensional heteronuclear NMR. Protein Sci. 1994, 3:372-390.
76. Chen A, Shapiro MJ NOE Pumping: A novel NMR technique for identification of compounds with binding affinity to macromolecules. J. Am. Chem. Soc. 1998, 120:10258-10259.
77. Cooke RM Protein NMR extends into new fields of structural biology. Curr. Opin. Chem. Biol. 1997, 1:359-364.
78. Kay LE NMR methods for the study of protein structure and dynamics. Biochem. Cell Biol. 1997, 75:1-15.
79. Hajduk PJ, Dinges J, Miknis GF, et al. NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein. J. Med. Chem. 1997, 40:3144-3150.
80. Hajduk PJ, Sheppard G, Nettesheim DG, et al. Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR. J. Am. Chem. Soc. 1997, 119:5818-5827.
81. Zask A, Levin JI, Killar LM, Skotnicki JS Inhibition of matrix metalloproteinases: Structure based design. Curr. Pharm. Des. 1996, 2:624-661.
82. Skiles JW, Gonnella NC, Jeng AY The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr. Med. Chem. 2001, 8:425-474.
83. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996, 274:1531-1534.
84. Hajduk PJ, Gerfin T, Boehlen J-M, Haeberli M, Marek D, Fesik SW High-throughput nuclear magnetic resonance-based screening. J. Med. Chem. 1999, 42:2315-2317.
85. 13C-labeled methyl groups. J. Am. Chem. Soc. 2000, 122:7898-7904.
86. Clore GM, Gronenborn AM Determining the structures of large proteins and protein complexes by NMR. Trends Biotechnol. 1998, 16:22-34.
87. Salzmann M, Wider G, Pervushin K, Senn H, Wüthrich K TROSY-type triple-resonance experiments for sequential NMR assignments of large proteins. J. Am. Chem. Soc. 1999, 121:844-848.
88. Pfister H Human papillomaviruses and skin cancer. Cancer Biol. 1992, 3:263-271.
89. Garcia-Carranca A, Gariglio PV Molecular aspects of human papillomaviruses and their relation to uterine cervix cancer. Rev. Invest. Clin. (Mexico) 1993, 45:85-92.
90. Meyer B, Weimar T, Peters T Screening mixtures for biological activity by NMR. Eur. J. Biochem. 1997, 246:705-709.
91. Matsushita Y, Gouda H, Tsujishita H, Hirono S Determination of binding conformations of drugs to human serum albumin by transferred nuclear Overhauser effect measurements and conformational analyses using high-temperature molecular dynamics calculations. J. Pharm. Sci. 1998, 87:379-386.
92. Dalvit C, Fogliatto G, Stewart A, Veronesi M, Stockman B WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability. J. Biomol. NMR 2001, 21:349-359.
93. Dalvit C, Pevarello P, Tato M, Veronesi M, Vulpetti A, Sundstrom M Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. J. Biomol. NMR 2000, 18:65-68.
94. Xue L, Bajorath J Molecular descriptors in chemoinformatics, computational combinatorial chemistry, and virtual screening. Comb. Chem. High Throughput Screen 2000, 3:363-372.
95. Lewis RA, Pickett SD, Clark DE Computer-aided molecular diversity analysis and combinatorial library design. Rev. Comput. Chem. 2000, 16:1-51.
96. Willett P Chemoinformatics - similarity and diversity in chemical libraries. Curr. Opin. Biotechnol. 2000, 11:85-88.
97. Spellmeyer DC, Grootenhuis PDJ Recent developments in molecular diversity. Computational approaches to combinatorial chemistry. Annu. Rep. Med. Chem. 1999, 34:287-296.
98. Gorse D, Lahana R Functional diversity of compound libraries. Curr. Opin. Chem. Biol. 2000, 4:287-294.
99. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliver. Rev. 1997, 23:3-25.
100. Lipinski CA Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2001, 44:235-249.
101. Fejzo J, Lepre CA, Peng JW, et al. The SHAPES strategy: An NMR-based approach for lead generation in drug discovery. Chem. Biol. 1999, 6:755-769.
102. Bemis GW, Murcko MA The properties of known drugs. 1. Molecular frameworks. J. Med. Chem. 1996, 39:2887-2893.
103. Matsuzawa A, Ichijo H Molecular mechanisms of the decision between life and death: Regulation of apoptosis by apoptosis signal-regulating kinase 1. J. Biochem. 2001, 130:1-8.
104. Altieri AS, Hinton DP, Byrd RA Association of biomolecular systems via pulsed field gradient NMR self-diffusion measurements. J. Am. Chem. Soc. 1995, 117:7566-7567.
105. Luxon BA, Gorenstein DG Comparison of x-ray and NMR-determined nucleic acid structures. Methods Enzymol. 1995, 261:45-73.
106. Wagner G, Hyberts SG, Havel TF NMR structure determination in solution: A critique and comparison with x-ray crystallography. Annu. Rev. Biophys. Biomol. Struct. 1992, 21:167-198.
107. Billeter M Comparison of protein structures determined by NMR in solution and by x-ray diffraction in single crystals. Q. Rev. Biophys. 1992, 25:325-377.
108. Hoffman DW, Cameron CS, Davies C, White SW, Ramakrishnan V Ribosomal protein L9: A structure determination by the combined use of x-ray crystallography and NMR spectroscopy. J. Mol. Biol. 1996, 264:1058-1071.
109. Shaanan B, Gronenborn AM, Cohen GH, et al. Combining experimental information from crystal and solution studies: joint x-ray and NMR refinement. Science 1992, 257:961-964.
110. Braun W, Epp O, Wüthrich K, Huber R Solution of the phase problem in the x-ray diffraction method for proteins with the nuclear magnetic resonance solution structure as initial model. Patterson search and refinement for the α-amylase inhibitor Tendamistat. J. Mol. Biol. 1989, 206:669-676.
111. Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res. 2000, 28:235-242.
112. Coombes RC, Marsh S, Gomm J, Johnston C Fibroblast growth factors and their receptors in breast and prostate cancer. Endo. Oncol. 2000, 237-254.
113. Moy FJ, Seddon AP, Boehlen P, Powers R High-resolution solution structure of basic fibroblast growth factor determined by multidimensional heteronuclear magnetic resonance spectroscopy. Biochemistry 1996, 35:13552-13561.
114. Moy FJ, Safran M, Seddon AP, et al. Properly oriented heparin-decasaccharide-induced dimers are the biologically active form of basic fibroblast growth factor. Biochemistry 1997, 36:4782-4791.
115. Ogura K, Nagata K, Hatanaka H, et al. Solution structure of human acidic fibroblast growth factor and interaction with heparin-derived hexasaccharide. J. Biomol. NMR 1999, 13:11-24.
116. Pineda-Lucena A, Jimenez MA, Lozano RM, et al. Three-dimensional structure of acidic fibroblast growth factor in solution: effects of binding to a heparin functional analog. J. Mol. Biol. 1996, 264:162-178.
117. Pineda-Lucena A, Jimenez MA, Nieto JL, Santoro J, Rico M, Gimenez-Gallego G 1H-NMR assignment and solution structure of human acidic fibroblast growth factor activated by inositol hexasulfate. J. Mol. Biol. 1994, 242:81-98.
118. Pellegrini L Role of heparan sulfate in fibroblast growth factor signalling: A structural view. Curr. Opin. Struct. Biol. 2001, 11:629-634.
119. Miyamoto M, Naruo K-I, Seko C, Matsumoto S, Kondo T, Kurokawa T Molecular cloning of a novel cytokine cDNA encoding the ninth member of the fibroblast growth factor family, which has a unique secretion property. Mol. Cell Biol. 1993, 13:4251-4259.
120. Folkman J, Klagsbrun M Angiogenic factors. Science 1987, 235:442-447.
121. Baird A, Bohlen P Peptide growth factors and their receptors. Handbook of Experimental Pharmacology 1990, 369-418. Springer-Verlag, New York. M.R.A. Sporn (Ed.).
122. Basilico C, Moscatelli D The FGF family of growth factors and oncogenes. Adv. Cancer Res. 1992, 59:115-165.
123. Ornitz DM FGFs, heparan sulfate and FGFRs: complex interactions essential for development. BioEssays 2000, 22:108-112.
124. Schlessinger J, Plotnikov AN, Ibrahimi OA, et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell 2000, 6:743-750.
125. Pellegrini L, Burke DF, Von Delft F, Mulloy B, Blundell TL Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 2000, 407:1029-1034.
126. DiGabriele AD, Lax I, Chen DI, et al. Structure of a heparin-linked biologically active dimer of fibroblast growth factor. Nature 1998, 393:812-817.
127. Manetti F, Corelli F, Botta M Fibroblast growth factors and their inhibitors. Curr. Pharm. Des. 2000, 6:1897-1924.
128. Fairbrother WJ, Champe MA, Christinger HW, Keyt BA, Starovasnik MA Solution structure of the heparin-binding domain of vascular endothelial growth factor. Structure 1998, 6:637-648.
129. Starovasnik MA, Christinger HW, Wiesmann C, Champe MA, de Vos AM, Skelton NJ Solution structure of the VEGF-binding domain of Flt-1: Comparison of its free and bound states. J. Mol. Biol. 1999, 293:531-544.
130. Campbell ID, Cooke RM Structure function relationships in EGF, TGF-α and IGFI. J. Cell Sci. Suppl. 1990, 13:5-10.
131. Montelione GT, Wuethrich K, Burgess AW, et al. Solution structure of murine epidermal growth factor determined by NMR spectroscopy and refined by energy minimization with restraints. Biochemistry 1992, 31:236-249.
132. Kohda D, Inagaki F Three-dimensional nuclear magnetic resonance structures of mouse epidermal growth factor in acidic and physiological pH solutions. Biochemistry 1992, 31:11928-11939.
133. Schlunegger MP, Guretter MG Refined crystal structure of human transforming growth factor b2 at 1.95 resolution. J. Mol. Biol. 1993, 231:445-458.
134. Harvey TS, Wilkinson AJ, Tappin MJ, Cooke RM, Campbell ID The solution structure of human transforming growth factor α Eur. J. Biochem. 1991, 198:555-562.
135. Hinck AP, Archer SJ, Qian SW, et al. Transforming growth factor β1: Three-dimensional structure in solution and comparison with the x-ray structure of transforming growth factor β2. Biochemistry 1996, 35:8517-8534.
136. Baxter RC Insulin-like growth factor (IGF)-binding proteins: Interactions with IGFs and intrinsic bioactivities. Am. J. Physiol. 2000, 278:E967-E976.
137. Sprang SR, Bazan JF Cytokine structural taxonomy and mechanisms of receptor engagement. Curr. Opin. Struct. Biol. 1993, 3:815-827.
138. Clore GM, Appella E, Yamada M, Matsushima K, Gronenborn AM Three-dimensional structure of interleukin 8 in solution. Biochemistry 1990, 29:1689-1696.
139. Gronenborn AM, Clore GM The three dimensional structure of interleukin-8. Challenges Mod. Med. 1994, 3:13-24.
140. Clore GM, Wingfield PT, Gronenborn AM High-resolution three-dimensional structure of interleukin 1b in solution by three- and four-dimensional nuclear magnetic resonance spectroscopy. Biochemistry 1991, 30:2315-2323.
141. Xie K Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 2001, 12:375-391.
142. Smith PC, Hobisch A, Lin D-L, Culig Z, Keller ET Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev. 2001, 12:33-40.
143. Mekhail T, Wood L, Bukowski R Interleukin-2 in cancer therapy: Uses and optimum management of adverse effects. BioDrugs 2000, 14:299-318.
144. Gurjal A, Philip PA Interleukin-2 in cancer. Emerging Drugs 2000, 5:273-285.
145. Maher DW, Davis I, Boyd AW, Morstyn G Human interleukin-4: An immunomodulator with potential therapeutic applications. Prog. Growth Factor Res. 1991, 3:43-56.
146. Gessner A, Rollinghoff M Biologic functions and signaling of the interleukin-4 receptor complexes. Immunobiology 2000, 201:285-307.
147. Murata T, Obiri NI, Debinski W, Puri RK Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem. Biophys. Res. Commun. 1997, 238:90-94.
148. Mintz A, Debinski W Cancer genetics/epigenetics and the X chromosome. Possible new links for malignant glioma pathogenesis and immune-based therapies. Crit. Rev. Oncog. 2000, 11:77-95.
149. Callard RE, Matthews DJ, Hibbert L IL-4 and IL-13 receptors: Are they one and the same?. Immunol. Today 1996, 17:108-110.
150. Powers R, Garrett DS, March CJ, Frieden EA, Gronenborn AM, Clore GM Three-dimensional solution structure of human interleukin-4 by multidimensional heteronuclear magnetic resonance spectroscopy. Science 1992, 256:1673-1677.
151. Powers R, Garrett DS, March CJ, Frieden EA, Gronenborn AM, Clore GM The high-resolution, three-dimensional solution structure of human interleukin-4 determined by multidimensional heteronuclear magnetic resonance spectroscopy. Biochemistry 1993, 32:6744-6762.
152. Redfield C, Smith LJ, Boyd J, et al. Analysis of the solution structure of human interleukin-4 determined by heteronuclear three-dimensional nuclear magnetic resonance techniques. J. Mol. Biol. 1994, 238:23-41.
153. Redfield C, Smith LJ, Boyd J, et al. Secondary structure and topology of human interleukin 4 in solution. Biochemistry 1991, 30:11029-11035.
154. Moy FJ, Diblasio E, Wilhelm J, Powers R Solution structure of human IL-13 and implication for receptor binding. J. Mol. Biol. 2001, 310:219-230.
155. Eisenmesser EZ, Horita DA, Altieri AS, Byrd RA Solution structure of interleukin-13 and insights into receptor engagement. J. Mol. Biol. 2001, 310:231-241.
156. Mott HR, Baines BS, Hall RM, et al. The solution structure of the F42A mutant of human interleukin 2. J. Mol. Biol. 1995, 247:979-994.
157. Xu G-Y, Yu H-A, Hong J, et al. Solution structure of recombinant human interleukin-6. J. Mol. Biol. 1997, 268:468-481.
158. Muhlhahn P, Zweckstetter M, Georgescu J, et al. Structure of interleukin 16 resembles a PDZ domain with an occluded peptide binding site. Nat. Struct. Biol. 1998, 5:682-686.
159. Woessner JF Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991, 5:2145-2154.
160. Ries C, Petrides E. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol. Chem. Hoppe-Seyler 1995, 376:345-355.
161. Moy FJ, Chanda PK, Cosmi S, et al. High-resolution solution structure of the inhibitor-free catalytic fragment of human fibroblast collagenase determined by multidimensional NMR. Biochemistry 1998, 37:1495-1504.
162. Moy FJ, Chanda PK, Chen JM, et al. NMR solution structure of the catalytic fragment of human fibroblast collagenase complexed with a sulfonamide derivative of a hydroxamic acid compound. Biochemistry 1999, 38:7085-7096.
163. 15N resonance assignments for a truncated and inhibited catalytic domain of matrix metalloproteinase-2. J. Biomol. NMR 2000, 17:85-86.
164. Li Y-C, Zhang X, Melton R, Ganu V, Gonnella NC Solution structure of the catalytic domain of human stromelysin-1 complexed to a potent, nonpeptidic inhibitor. Biochemistry 1998, 37:14048-14056.
165. Van Doren SR, Kurochkin AV, Hu W, et al. Solution structure of the catalytic domain of human stromelysin complexed with a hydrophobic inhibitor. Protein Sci. 1995, 4:2487-2498.
166. Gooley PR, O'Connell JF, Marcy AI, et al. The NMR structure of the inhibited catalytic domain of human stromelysin-1. Nat. Struct. Biol. 1994, 1:111-118.
167. Moy FJ, Chanda PK, Chen JM, et al. High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor. J. Mol. Biol. 2000, 302:671-689.
168. Zhang X, Gonnella NC, Koehn J, et al. Solution structure of the catalytic domain of human collagenase-3 (MMP-13) complexed to a potent non-peptidic sulfonamide inhibitor: Binding comparison with stromelysin-1 and collagenase-1. J. Mol. Biol. 2000, 301:513-524.
169. Morphy JR, Millican TA, Porter JR Matrix metalloproteinase inhibitors: Current status. Curr. Med. Chem. 1995, 2:743-762.
170. Drummond AH, Beckett P, Brown PD, et al. Preclinical and clinical studies of MMP inhibitors in cancer. Ann. N.Y. Acad. Sci. 1999, 878:228-235.
171. Belotti D, Paganoni P, Giavazzi R MMP inhibitors: Experimental and clinical studies. Int. J. Biol. Markers 1999, 14:232-238.
172. De B, Natchus MG, Cheng M, et al. The next generation of MMP inhibitors: Design and synthesis. Ann. N.Y. Acad. Sci. 1999, 878:40-60.
173. Clore GM, Gronenborn AM New methods of structure refinement for macromolecular structure determination by NMR. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:5891-5898.
174. Cornilescu G, Delaglio F, Bax A Protein backbone angle restraints from searching a database for chemical shift and sequence homology. J. Biomol. NMR 1999, 13:289-302.
175. Kuszewski J, Gronenborn AM, Clore GM Improving the quality of NMR and crystallographic protein structures by means of a conformational database potential derived from structure databases. Protein Sci. 1996, 5:1067-1080.
176. Kuszewski J, Gronenborn AM, Clore GM Improvements and extensions in the conformational database potential for the refinement of NMR and x-ray structures of proteins and nucleic acids. J. Magn. Reson. 1997, 125:171-177.
177. Kuszewski J, Gronenborn AM, Clore GM Improving the packing and accuracy of NMR structures with a pseudopotential for the radius of gyration. J. Am. Chem. Soc. 1999, 121:2337-2338.
178. Tjandra N, Bax A Direct measurement of distances and angles in biomolecules by NMR in a dilute liquid crystalline medium. Science 1997, 278:1111-1274. [see comments] [published erratum appears in Science 1997 Dec 5; 278(5344):1697].
179. Clore GM, Starich MR, Bewley CA, Cai M, Kuszewski J Impact of residual dipolar couplings on the accuracy of NMR structures determined from a minimal number of NOE restraints. J. Am. Chem. Soc. 1999, 121:6513-6514.
180. Gardner KH, Rosen MK, Kay LE Global folds of highly deuterated, methyl-protonated proteins by multidimensional NMR. Biochemistry 1997, 36:1389-1401.
181. Huang X, Moy F, Powers R Evaluation of the utility of NMR structures determined from minimal NOE-based restraints for structure-based drug design, using MMP-1 as an example. Biochemistry 2000, 39:13365-13375.
182. Brunner E. Residual dipolar couplings in protein NMR. Concepts Magnetic Res. 2001, 13:238-259.
183. Nilges M, Gronenborn AM, Bruenger AT, Clore GM Determination of three-dimensional structures of proteins by simulated annealing with interproton distance restraints. Application to crambin, potato carboxypeptidase inhibitor and barley serine proteinase inhibitor 2. Protein Eng. 1988, 2:27-38.
184. Brunger AT X-PLOR Version 3.1 Manual 1993, Yale University, New York.
185. 13Cβ chemical shifts on protein structure determination by NMR. J. Magn. Reson. Ser. B 1995, 106:92-96.
186. Petros AM, Kawai M, Luly JR, Fesik SW Conformation of two non-immunosuppressive FK506 analogs when bound to FKBP by isotope-filtered NMR. FEBS Lett. 1992, 308:309-314.
187. Ikura M, Bax A. Isotope-filtered 2D NMR of a protein-peptide complex: Study of a skeletal muscle myosin light chain kinase fragment bound to calmodulin. J. Am. Chem. Soc. 1992, 114:2433-2440.
188. Gemmecker G, Olejniczak ET, Fesik SW An improved method for selectivity observing protons attached to carbon-12 in the presence of proton-carbon-13 spin pairs. J. Magn. Reson. 1992, 96:199-204.
189. Marion D, Driscoll PC, Kay LE, et al. Overcoming the overlap problem in the assignment of proton NMR spectra of larger proteins by use of three-dimensional heteronuclear proton-nitrogen-15 Hartmann-Hahn-multiple quantum coherence and nuclear Overhausermultiple quantum coherence spectroscopy: Application to interleukin 1β Biochemistry 1989, 28:6150-6156.
190. Zuiderweg ERP, Fesik SW Heteronuclear three-dimensional NMR spectroscopy of the inflammatory protein C5a. Biochemistry 1989, 28:2387-2391.
191. Chen JM, Nelson FC, Levin JI, et al. Structure-based design of a novel, potent, and selective inhibitor for MMP-13 utilizing NMR spectroscopy and computer-aided molecular design. J. Am. Chem. Soc. 2000, 122:9648-9654.
192. Palmer AG Probing molecular motion by NMR. Curr. Opin. Struct. Biol. 1997, 7:732-737.
193. Kay LE Protein dynamics from NMR. Biochem. Cell Biol. 1998, 76:145-152.
194. Ishima R, Torchia DA Protein dynamics from NMR. Nat. Struct. Biol. 2000, 7:740-743.
195. Lipari G, Szabo A. Model-free approach to the interpretation of nuclear magnetic resonance relaxation in macromolecules. 1. Theory and range of validity. J. Am. Chem. Soc. 1982, 104:4546-4559.
196. Lipari G, Szabo A. Model-free approach to the interpretation of nuclear magnetic resonance relaxation in macromolecules. 2. Analysis of experimental results. J. Am. Chem. Soc. 1982, 104:4559-4570.
197. Moy FJ, Pisano MR, Chanda PK, et al. Assignments, secondary structure and dynamics of the inhibitor-free catalytic fragment of human fibroblast collagenase. J. Biomol. NMR 1997, 10:9-19.
198. 15N NMR relaxation measurements: Comparison of ligand binding to the S1-S3 and S1'-S3' subsites. J. Biomol. NMR 1999, 15:55-64.
199. Zhang X, Gonnella NC, Koehn J, et al. Solution structure of the
200. Lovejoy B, Welch AR, Carr S, et al. Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors. Nat. Struct. Biol. 1999, 6:217-221.
201. Ringe D, Petsko GA Study of protein dynamics by x-ray diffraction. Methods Enzymol. 1986, 131:389-433.
202. Powers R, Clore GM, Garrett DS, Gronenborn AM Relationships between the precision of high-resolution protein NMR structures, solution-order parameters, and crystallographic B factors. J. Magn. Reson. Ser. B 1993, 101:325-327.
203. 15N NMR relaxation study. Proteins Struct. Funct. Genet. 2000, 41:460-474.
204. 13CO) NMR relaxation and computational molecular dynamics. Biochemistry 2002, 41:2655-2666.
205. Uhrinova S, Smith MH, Jameson GB, Uhrin D, Sawyer L, Barlow PN Structural changes accompanying pH-induced dissociation of the β-lactoglobulin dimer. Biochemistry 2000, 39:3565-3574.
206. Zhang P, Dayie KT, Wagner G Unusual lack of internal mobility and fast overall tumbling in oxidized flavodoxin from Anacystis nidulans. J. Mol. Biol. 1997, 272:443-455.
207. Constantine KL, Friedrichs MS, Goldfarb V, Jeffrey PD, Sheriff S, Mueller L Characterization of the backbone dynamics of an anti-digoxin antibody VL domain by inverse detected protonnitrogen-15 NMR: Comparisons with x-ray data for the Fab. Proteins Struct. Funct. Genet. 1993, 15:290-311.
208. Roboz J Mass spectrometry in cancer research. Adv. Cancer Res. 1978, 27:201-267.
209. Roboz J. Mass Spectrometry in Cancer Research 2002, CRC Press, New Haven, CT.
210. Chistyakov VV, Anisimova OS, Sheinker YN, Safonova TS Mass spectra of antitumor drugs containing phosphoric and thiophosphoric acid ethylenimides. Khim. Farm. Zh. 1984, 18:1290-1294.
211. Pyatigorskaya TL, Zhil'kova OY, Shelkovskii VS, Arkhangelova NM, Grizodub AI, Sukhodub LF Hydrolysis of 1,1,1"-phosphinothioylidinetrisaziridine thiotepa in aqueous solution. Biomed. Environ. Mass Spectrom. 1987, 14:143-148.
212. Kosevich MV, Shelkovskii VS On the formation of doubly charged fragment and cluster ions of oxygen- and sulfur-containing substances in field ionization and field desorption mass spectrometry. Rapid Commun. Mass Spectrom. 1990, 4:493-494.
213. Sukhodub LF Soft-ionization mass spectrometry study of deoxynucleoside bioclusters and deoxynucleoside-antitumor medicinal preparation clusters. Mass Spectrom. Rev. 1996, 14:235-254.
214. Kosevich MV, Shelkovsky VS, Stepanian SG Dependence of the biological activity and mass spectrometric pattern on the structure peculiarities of the molecule of alkylating drug thiotepa. Biophys. Chem. 1996, 57:123-131.
215. Musser SM, Pan SS, Callery PS Liquid chromatography-thermospray mass spectrometry of DNA adducts formed with mitomycin C, porfiromycin and thiotepa. J. Chromatogr. 1989, 474:197-207.
216. Musser SM, Callery PS Supercritical fluid chromatography/chemical ionization/mass spectrometry of some anticancer drugs in a thermospray ion source. Biomed. Environ. Mass Spectrom. 1990, 19:348-352.
217. Sukhodub LF, Kosevich MV, Shelkovskii VS, Pyatigorskaya TL, Zhilkova OY Direct detection of nitrogen base-thiotepa adducts by mild ionization mass spectrometry. Biofizika 1990, 35:549-551.
218. Van Maanen MJ, Tijhof IM, Damen JMA, et al. A search for new metabolites of N,N',N″-triethylenethiophosphoramide. Cancer Res. 1999, 59:4720-4724.
219. Sukhodub LF, Chivanov VD, Grebenik LI, Bondarenko PV, Zubarev RA, Knysh AN Study of triethylenethiophosphamide interaction with nucleotides by mass spectrometry with ionization by fission fragments californium-252. Ukr. Biokhim. Zh. 1992, 64:41-49.
220. van Maanen MJ, Beijnen JH Liquid chromatographic-mass spectrometric determination of the novel, recently identified thioTEPA metabolite, thioTEPA-mercapturate, in urine. J. Chromatogr. B: Biomed. Sci. Appl. 1999, 732:73-79.
221. Bakhtiar R In vitro exposure of human hemoglobin to the antineoplastic drug thiotepa. Rapid Commun. Mass Spectrom. 2000, 14:534-537.
222. van Maanen MJ, Doesburg Smits K, Damen JMA, Heck AJR, Beijnen JH Stability of thioTEPA and its metabolites, TEPA, monochloroTEPA and thioTEPA-mercapturate, in plasma and urine. Int. J. Pharm. 2000, 200:187-194.
223. van Maanen MJ, Brandt AC, Damen JMA, Beijnen JH Degradation study of thiotepa in aqueous solutions. Int. J. Pharm. 1999, 179:55-64.
224. Cohen BE, Egorin MJ, Nayar MSB, Gutierrez PL Effects of pH and temperature on the stability and decomposition of N,N',N″-triethylenethiophosphoramide in urine and buffer. Cancer Res. 1984, 44:4312-4316.
225. Pyatigorskaya TL, Zhilkova OY, Shelkovskii VS, et al. Analysis of the products of thiophosphamide transformation in aqueous solutions using thin-layer chromatography and mass spectrometry. Khim. Farm Zh. 1985, 19:1235-1241.
226. Chistyakov VV, Anisimova OS, Presnova ZF, et al. Study on the metabolism of the antineoplastic agent thiophosphamide in rats. Khim. Farm Zh. 1988, 22:1158-1162.
227. Van Maanen RJ, Van Ooijen RD, Zwikker JW, Huitema ADR, Rodenhuis S, Beijnen JH Determination of N,N'N″-triethylenethiophosphoramide and its active metabolite N,N'N″-triethylenephosphoramide in plasma and urine using capillary gas chromatography. J. Chromatogr. B: Biomed. Sci. Appl. 1998, 719:103-112.
228. Van Maanen MJ, Huitema ADR, Rodenhuis S, Beijnen JH Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin. Anticancer Drugs 2001, 12:519-524.
229. Srivastava SK, Singhal SS, Hu X, Awasthi YC, Zimniak P, Singh SV Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. Arch. Biochem. Biophys. 1999, 366:89-94.
230. Chistyakov VV, Anisimova OS, Losev GA, Chernov VA, Sheinker YN Hydrazine sulfate, an oxidative desulfation inhibitor for thiophosphamide and thiodipin. Khim. Farm. Zh. 1989, 23:1291-1294.
231. Huitema ADR, Tibben MM, Kerbusch T, Den Bosch JJK-V, Rodenhuis S, Beijnen JH High performance liquid chromatographic determination of the stabilized cyclophosphamide metabolite 4-hydroxycyclophosphamide in plasma and red blood cells. J. Liq. Chromatogr. Relat. Technol. 2000, 23:1725-1744.
232. Sukhodub LF, Shelkovskii VS, Kosevich MV, Pyatigorskaya TL, Zhilkova OY Nucleic acid base complexes with thiotepa as revealed by field ionization mass spectrometry. Biomed. Environ. Mass Spectrom. 1986, 13:167-170.
233. Sukhodub LF, Shelkovskii VS, Kosevich MV, Pyatigorskaya TL, Zhilkova OI Mass-spectrometric study of the interaction between thiophosphamide and nucleic acid bases. Dokl. Akad. Nauk. SSSR 1985, 283:714-716.
234. Andrievskii GV, Nikolaeva MI, Serebryanyi AM, Tantsyrev GD, Sharova OL Analysis of canonical and modified components of nucleic acids by fast-atom-bombardment secondaryion mass spectrometry. Zh. Anal. Khim. 1988, 43:1850-1856.
235. Sukhodub LF, Andrievskii GV, Pyatigorskaya TL, Kosevich MV, Zhilkova OY Identification of DNA-thiotepa adducts by fast atom bombardment mass spectrometry. Bioorg. Khim. 1988, 14:1698-1699.
236. Sukhodub LF, Chivanov VD, Grebenik LI, Bondarenko PV, Zubarev RA, Knysh AN Observation of thiotepa deoxyguanosine 5'-phosphate modification products by PDMS. Bioorg. Khim. 1991, 17:999-1001.
237. Andrievskii GV, Sukhodub LF, Pyatigorskaya TL, Boryak OA, Limanskaya OY, Shelkovskii VS Direct observation of the alkylation products of deoxyguanosine and DNA by fast atom bombardment mass spectrometry. Biol. Mass Spectrom. 1991, 20:665-668.
238. Voloshchuk TP, Patskovsky YV, Potopalsky AI Alkylation of nucleic acid components by ethylenimine derivatives. 2. Alkylation of nucleosides. Bioorg. Khim. 1993, 19:484-493.
239. Hignite CE, Azarnoff DL Identification of methotrexate and folic acid analogs by mass spectrometry. Biomed. Mass Spectrom. 1978, 5:161-163.
240. Smith RG, Pegues JC, Farquhar D, Loo TL, Wang Y-M Mass spectrometry of permethylated folic acid analogs. Biomed. Mass Spectrom. 1981, 8:144-148.
241. Cheung HTA, Tattam BN, Antonjuk DJ, Boadle DK Ammonia and methane chemical ionization mass spectra of methotrexate and its amide and ester analogs. Biomed. Mass Spectrom. 1985, 12:11-18.
242. Przybylski M Identification of metabolism pathways of anticancer drugs by high-pressure liquid chromatography in combination with field desorption mass spectrometry. Biomed. Mass Spectrom. 1982, 9:995-1012.
243. Przybylski M, Preiss J, Dennebaum R, Fischer J Identification and quantitation of methotrexate and methotrexate metabolites in clinical high-dose therapy by high-pressure liquid chromatography and field desorption mass spectrometry. Biomed. Mass Spectrom. 1982, 9:22-32.
244. Morris HR, Riddoch A, Chapman JR, Aspinal ML, Compson KR, McDowell RA Field desorption and chemical ionization analysis using a double beam mass spectrometer. Adv. Mass Spectrom. 1978, 7B:832-837.
245. Tatischeff I, Spiro M, Della Negra S, et al. Plasma desorption mass spectrometry (PDMS) of folic acid and derivatives. Int. J. Mass Spectrom. Ion Phys. 1983, 48:165-168.
246. Cairnes DA, Evans WE A simple preparation of the methotrexate metabolites 7-hydroxymethotrexate and 4-deoxy-4-amino-N10-methylpteroic acid. Ther. Drug Monit. 1983, 5:363-366.
247. Eicke A, Anders V, Junack M, Sichtermann W, Benninghoven A Secondary ion mass spectrometry of folic acid analogs. Int. J. Mass Spectrom. Ion Phys. 1983, 46:479-482.
248. Eicke A, Anders V, Junack M, Sichtermann W, Benninghoven A Secondary ion mass spectrometry of folic acid analogs. Anal. Chem. 1983, 55:178-182.
249. Deng Y, Zeng H, Unger SE, Wu J-T Multiple-sprayer tandem mass spectrometry with parallel high flow extraction and parallel separation for high-throughput quantitation in biological fluids. Rapid Commun. Mass Spectrom. 2001, 15:1634-1640.
250. Rule G, Chapple M, Henion J A 384-well solid-phase extraction for LC/MS/MS determination of methotrexate and its 7-hydroxy metabolite in human urine and plasma. Anal. Chem. 2001, 73:439-443.
251. Widemann BC, Sung E, Anderson L, et al. Pharmacokinetics and metabolism of the methotrexate metabolite 2,4-diamino-N10-methylpteroic acid. J. Pharmacol. Exp. Ther. 2000, 294:894-901.
252. Steinborner S, Henion J Liquid-liquid extraction in the 96-well plate format with SRM LC/MS quantitative determination of methotrexate and its major metabolite in human plasma. Anal. Chem. 1999, 71:2340-2345.
253. Turci R, Micoli G, Minoia C Determination of methotrexate in environmental samples by solid phase extraction and high performance liquid chromatography: Ultraviolet or tandem mass spectrometry detection. Rapid Commun. Mass Spectrom. 2000, 14:685-691.
254. Hignite CE, Shen DD, Azarnoff DL Separation and identification of impurities in parenteral methotrexate dosage forms. Cancer Treat. Rep. 1978, 62:13-18.
255. Siegel MM, Hollander IJ, Hamann PR, et al. Matrix-assisted UV-laser desorption/ionization mass spectrometric analysis of monoclonal antibodies for the determination of carbohydrate, conjugated chelator, and conjugated drug content. Anal. Chem. 1991, 63:2470-2481.
256. Nikolic D, van Breemen RB Screening for inhibitors of dihydrofolate reductase using pulsed ultrafiltration mass spectrometry. Comb. Chem. High Throughput Screen 1998, 1:47-55.
257. Chiccarelli FS, Morrison JA, Cosulich DB, et al. Identification of human urinary mitoxantrone metabolites. Cancer Res. 1986, 46:4858-4861.
258. Blanz J, Mewes K, Ehninger G, et al. Isolation and structure elucidation of urinary metabolites of mitoxantrone. Cancer Res. 1991, 51:3427-3433.
259. Blanz J, Mewes K, Ehninger G, et al. Evidence for oxidative activation of mitoxantrone in human, pig, and rat. Drug Metab. Dispos. 1991, 19:871-880.
260. Mewes K, Blanz J, Ehninger G, Gebhardt R, Zeller KP Cytochrome P-450-induced cytotoxicity of mitoxantrone by formation of electrophilic intermediates. Cancer Res. 1993, 53:5135-5142.
261. Mewes K, Blanz J, Freund S, Ehninger G, Zeller KP Synthesis and structural elucidation of biliary excreted thioether derivatives of mitoxantrone. Xenobiotica 1994, 24:199-213.
262. Siegel MM Hydrogen-deuterium exchange studies utilizing a thermospray mass spectrometer interface. Anal. Chem. 1988, 60:2090-2095.
263. Reddy AM, Mykytyn VV, Schram KH Deuterium-labeled 3-nitrobenzyl alcohol as a matrix for fast atom bombardment mass spectrometry. Biomed. Environ. Mass Spectrom. 1989, 18:1087-1095.
264. Sepetov NF, Issakova OL, Lebl M, Swiderek K, Stahl DC, Lee TD The use of hydrogendeuterium exchange to facilitate peptide sequencing by electrospray tandem mass spectrometry. Rapid Commun. Mass Spectrom. 1993, 7:58-62.
265. Spengler B, Luetzenkirchen F, Kaufmann R On-target deuteration for peptide sequencing by laser mass spectrometry. Org. Mass Spectrom. 1993, 28:1482-1490.
266. Siegel MM, Bitha P, Child RG, Hlavka JJ, Lin YI, Chang TT Fast atom bombardment mass spectrometry of cisplatin analogs. Biomed. Environ. Mass Spectrom. 1986, 13:25-32.
267. Martin LB, Schreiner AF, Van Breemen RB Characterization of cisplatin adducts of oligonucleotides by fast atom bombardment mass spectrometry. Anal. Biochem. 1991, 193:6-15.
268. Cetini G, Operti L, Vaglio GA, Bandini AL, Banditelli G, Minghetti G Fast atom bombardment mass spectrometry of neutral methanide and ionic carbene platinum (II) derivatives. Org. Mass Spectrom. 1989, 24:479-484.
269. Claerboudt J, De Spiegeleer B, Lippert B, De Bruijn EA, Claeys M Fast atom bombardment and tandem mass spectrometry for the structural characterization of cisplatin analogs and bis-nucleobase adducts with cisplatin. Spectroscopy (Ottawa) 1989, 7:91-112.
270. Bruce DW, Cole-Hamilton DJ, Cottee FH, Page JA A fast atom bombardment mass spectrometric investigation of some triethylphosphine complexes of platinum (II) in aqueous solution. J. Organomet. Chem. 1987, 320:249-255.
271. Burns RB, Burton RW, Albon SP, Embree L Liquid chromatography-mass spectrometry for the detection of platinum antineoplastic complexes. J. Pharm. Biomed. Anal. 1996, 14:367-372.
272. Poon GK, Mistry P, Lewis S Electrospray ionization mass spectrometry of platinum anticancer agents. Biol. Mass Spectrom. 1991, 20:687-692.
273. Bergamini P, Bortolini O, Curcuruto O, Hamdan M Investigation of bisdiphenylphosphinomethane Pt (II) complexes by electrospray and fast atom bombardment mass spectrometry. J. Mass Spectrom. 1995, S77-S84. Spec. Issue.
274. Allain P, Heudi O, Cailleux A, et al. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients. Drug Metab. Dispos. 2000, 28:1379-1384.
275. Costello CE, Nordhoff E, Hillenkamp F Matrix-assisted UV and IR laser desorption-ionization time-of-flight mass spectrometry of diamminoplatinum (II) oligodeoxyribonucleotide adducts and their unplatinated analogs. Int. J. Mass Spectrom. Ion Proc. 1994, 132:239-249.
276. Guittard J, Pacifico C, Blais JC, Bolbach G, Chottard JC, Spassky A Matrix-assisted laser desorption ionization time-of-flight mass spectrometry of DNA-PtII complexes. Rapid Commun. Mass Spectrom. 1995, 9:33-36.
277. Costello CE, Comess KM, Plaziak AS, Bancroft DP, Lippard SJ Fast atom bombardment and high performance tandem mass spectrometry of platinum (II) oligodeoxyribonucleotide fragments. Int. J. Mass Spectrom. Ion Proc. 1992, 122:255-279.
278. -). Anal. Biochem. 2000, 284:77-86.
279. 2+ by enzymatic degradation of the products and ESI and MALDI mass spectrometries. J. Mass Spectrom. 1996, 31:802-809.
280. Gibson D, Costello CE A mass spectral study of the binding of the anticancer drug cisplatin to ubiquitin. Eur. Mass Spectrom. 1999, 5:501-510.
281. Heudi O, Brisset H, Cailleux A, Allain P Chemical instability and methods for measurement of cisplatin adducts formed by interactions with cysteine and glutathione. Int. J. Clin. Pharmacol. Ther. 2001, 39:344-349.
282. Zollner P, Zenker A, Galanski M, Keppler BK, Lindner W Reaction monitoring of platinum (II) complex-5'-guanosine monophosphate adduct formation by ion exchange liquid chromatography/electrospray ionization mass spectrometry. J. Mass Spectrom. 2001, 36:742-753.
283. Kung A, Strickmann DB, Galanski M, Keppler BK Comparison of the binding behavior of oxaliplatin, cisplatin and analogues to 5'-GMP in the presence of sulfur-containing molecules by means of capillary electrophoresis and electrospray mass spectrometry. J. Inorg. Biochem. 2001, 86:691-698.
284. 3], diethylenetriamine and terpyridine M = gly-gly, ala-gly and gly-ala]. Eur. J. Mass Spectrom. 2001, 7:69-78.
285. Liu Q, Zhang J, Ke X, Mei Y, Zhu L, Guo Z ESMS and NMR investigations on the interaction of the anticancer drug cisplatin and chemopreventive agent selenomethionine. J. Chem. Soc. Dalton Trans. 2001, 6:911-916.
286. Warnke U, Gysler J, Hofte B, et al. Separation and identification of platinum adducts with DNA nucleotides by capillary zone electrophoresis and capillary zone electrophoresis coupled to mass spectrometry. Electrophoresis 2001, 22:97-103.
287. Mio T, Sumino K FAB mass spectrometry of carboplatin and its metabolite in the urine. Iyo Masu Kenkyukai Koenshu 1987, 12:207-210.
288. Poon GK, Mistry P, Raynaud FI, Harrap KR, Murrer BA, Barnard CFJ Determination of metabolites of a novel platinum anticancer drug JM216 in human plasma ultrafiltrates. J. Pharm. Biomed. Anal. 1995, 13:1493-1498.
289. Enediyne Antibiotic Antitumor Agents 1995, Dekker, Boca Raton, FL. D.B. Borders, T.W. Doyle (Eds.).
290. Lee MD, Dunne TS, Siegel MM, Chang CC, Morton GO, Borders DB Calicheamicins, a novel family of antitumor antibiotics. 1. Chemistry and partial structure of calichemicin γ1I. J. Am. Chem. Soc. 1987, 109:3464-3466.
291. Lee MD, Dunne TS, Chang CC, et al. Calicheamicins, a novel family of antitumor antibiotics. 2. Chemistry and structure of calicheamicin γ 1I. J. Am. Chem. Soc. 1987, 109:3466-3468.
292. Lee MD, Dunne TS, Chang CC, et al. Calicheamicins, a novel family of antitumor antibiotics. 4. Structure elucidation of calicheamicins β1Br, γ1Br, α2I, α3I, β1I, γ1I, and δ1I. J. Am. Chem. Soc. 1992, 114:985-997.
293. Lee MD Identification, isolation, and structure determination [of Calecheamicins]. Enediyne Antibiotic Antitumor Agents 1995, Dekker, New York. D.B. Borders, T.D. Doyle (Eds.).
294. Golik J Structure determination of the esperamicins. Enediyne Antibiotic Antitumor Agents 1995, 187-215. Dekker, New York. D.B. Borders, T.W. Doyle (Eds.).
295. Lam KS, Veitch JA Biosynthesis of esperamicin. Enediyne Antibiotic Antitumor Agents 1995, 217-237. Dekker, New York. D.B. Borders, T.W. Doyle (Eds.).
296. Chin DH, Zeng CH, Costello CE, Goldberg IH Sites in the diyne-ene bicyclic core of neocarzinostatin chromophore responsible for hydrogen abstraction from DNA. Biochemistry 1988, 27:8106-8114.
297. Gao Q, Cheng X, Smith RD, Yang CF, Goldberg IH Binding specificity of post-activated neocarzinostatin chromophore drug-bulged DNA complex studied using electrospray ionization mass spectrometry. J. Mass Spectrom. 1996, 31:31-36.
298. Hamann PR, Hinman LM, Hollander I, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjugate Chem. 2002, 13:47-58.
299. Hamann PR, Hinman LM, Beyer CF, et al. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjugate Chem. 2002, 13:40-46.
300. Siegel MM, Tabei K, Kunz A, et al. Calicheamicin derivatives conjugated to monoclonal antibodies: Determination of loading values and distributions by infrared and UV matrix-assisted laser desorption/ionization mass spectrometry and electrospray ionization mass spectrometry. Anal. Chem. 1997, 69:2716-2726.
301. Siegel MM Determination of loading values and distributions for drugs conjugated to proteins and antibodies by MALDI-MS and ESI-MS. Methods Mol. Biol. (Totowa NJ) 1996, 61:211-226.
302. Siegel MM, Tsou HR, Lin B, et al. Determination of the loading values for high levels of drugs and sugars conjugated to proteins by matrix-assisted ultraviolet laser desorption/ionization mass spectrometry. Biol. Mass. Spectrom 1993, 22:369-376.
303. Siegel MM, Tabei K, Tsao R, et al. Comparative mass spectrometric analyses of photofrin oligomers by fast atom bombardment mass spectrometry, UV and IR matrix-assisted laser desorption/ionization mass spectrometry, electrospray ionization mass spectrometry and laser desorption/jet-cooling photoionization mass spectrometry. J. Mass Spectrom. 1999, 34:661-669.
304. Pandey RK, Siegel MM, Tsao R, McReynolds JH, Dougherty TJ Fast atom bombardment mass spectral analyses of Photofrin II and its synthetic analogs. Biomed. Environ. Mass Spectrom. 1990, 19:405-414.
305. Cai H, Wang Q, Luo J, Lim CK Study of temoporfin metabolism by HPLC and electrospray mass spectrometry. Biomed. Chromatogr. 1999, 13:354-359.
306. Lord GA, Cai H, Luo JL, Lim CK HPLC-electrospray mass spectrometry for the analysis of temoporfin-polyethylene glycol conjugates. Analyst (Cambridge, UK) 2000, 125:605-608.
307. Angotti M, Maunit B, Muller J-F, Bezdetnaya L, Guillemin F Characterization by matrix-assisted laser desorption/ionization Fourier transform ion cyclotron resonance mass spectrometry of the major photoproducts of Temporfin μ-THPC and bacteriochlorin μ-THPBC. J. Mass Spectrom. 2001, 36:825-831.
308. Angotti M, Maunit B, Muller J-F, Bezdetnaya L, Guillemin F Matrix-assisted laser desorption/ionization coupled to Fourier transform ion cyclotron resonance mass spectrometry: A method to characterize temoporfin photoproducts. Rapid Commun. Mass Spectrom. 1999, 13:597-603.
309. Jones RM, Wang Q, Lamb JH, Djelal BD, Bonnett R, Lim CK Identification of photochemical oxidation products of 5,10,15,20-tetram-hydroxyphenyl)chlorin by online HPLC-electrospray ionization tandem mass spectrometry. J. Chromatogr. A 1996, 722:257-265.
310. Miller RW, Powell RG, Smith CR, Arnold E, Clardy J Antileukemic alkaloids from Taxus wallichiana Zucc. J. Org. Chem. 1981, 46:1469-1474.
311. Ringel I, Horwitz SB Taxol is converted to 7-epitaxol, a biologically active isomer, in cell culture medium. J. Pharmacol. Exp. Ther. 1987, 242:692-698.
312. Zamir LO, Nedea ME, Zhou Z-H, et al. Taxus canadensis taxanes: Structures and stereochemistry. Can. J. Chem. 1995, 73:655-665.
313. Monsarrat B, Mariel E, Cros S, et al. Taxol metabolism. Isolation and identification of three major metabolites of taxol in rat bile. Drug Metab. Dispos. 1990, 18:895-901.
314. Walle T, Kumar GN, McMillan JM, Thornburg KR, Walle UK Taxol metabolism in rat hepatocytes. Biochem. Pharmacol. 1993, 46:1661-1664.
315. Monsarrat B, Alvinerie P, Gares M, et al. Hepatic metabolism and biliary excretion of taxol. Cell Pharmacol. 1993, 1:S77-S81.
316. Royer I, Alvinerie P, Armand JP, Ho LK, Wright M, Monsarrat B Paclitaxel metabolites in human plasma and urine: identification of 6α-hydroxytaxol, 7-epitaxol and taxol hydrolysis products by liquid chromatography/atmospheric-pressure chemical ionization mass spectrometry. Rapid Commun. Mass Spectrom. 1995, 9:495-502.
317. Sparreboom A, Huizing MT, Boesen JJB, Nooijen WJ, van Tellingen O, Beijnen JH Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces. Cancer Chemother. Pharmacol. 1995, 36:299-304.
318. Royer I, Monsarrat B, Sonnier M, Wright M, Cresteil T Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res. 1996, 56:58-65.
319. Poon GK, Bloomer JW, Clarke SE, Maltas J Rapid screening of taxol metabolites in human microsomes by liquid chromatography/electrospray ionization-mass spectrometry. Rapid Commun. Mass Spectrom. 1996, 10:1165-1168.
320. Sottani C, Minoia C, Colombo A, Zucchetti M, D'Incalci M, Fanelli R Structural characterization of mono- and dihydroxylated metabolites of paclitaxel in rat bile using liquid chromatography/ion spray tandem mass spectrometry. Rapid Commun. Mass Spectrom. 1997, 11:1025-1032.
321. Hauck C Structure elucidation of taxol metabolites by liquid chromatography/mass spectrometry and species differences in taxol metabolism. Rapid Commun. Mass Spectrom. 1997, 11:1823.
322. Sottani C, Minoia C, Colombo T, Zucchetti M, D'Incalci M, Fanelli R Structure elucidation of taxol metabolites by liquid chromatography/mass spectrometry and species differences in taxol metabolism. Reply. Rapid Commun. Mass Spectrom. 1997, 11:1824.
323. Dierks EA, Stams KR, Lim H-K, Cornelius G, Zhang H, Ball SE A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab. Dispos. 2001, 29:23-29.
324. McClure TD, Schram KH, Reimer MLJ The mass spectrometry of taxol. J. Am. Soc. Mass Spectrom. 1992, 3:672-679.
325. McClure TD, Schram KH, Reimer MLJ The mass spectrometry of taxol. J. Am. Soc. Mass Spectrom. 1993, 4:85.
326. Hoke SH, Wood JM, Cooks RG, Li XH, Chang CJ Rapid screening for taxanes by tandem mass spectrometry. Anal. Chem. 1992, 64:2313-2315.
327. Griffini A, Peterlongo F, De Bellis P, Pace R Desorption chemical ionization and thermospray mass spectra of taxol and related compounds. Fitoterapia 1993, 64:53-81.
328. Auriola SOK, Lepisto AM, Naaranlahti T, Lapinjoki SP Determination of taxol by high-performance liquid chromatography-thermospray mass spectrometry. J. Chromatogr. 1992, 594:153-158.
329. Madhusudanan KP Formation of radical anion adduct between Paclitaxel and matrix under fast-atom bombardment. Rapid Commun. Mass Spectrom. 1997, 11:295-297.
330. Takayama M, Kataoka H, Katagi T, et al. A new versatile matrix for fast atom bombardment mass spectrometry. J. Mass Spectrom. Soc. Jpn. 1998, 46:143-149.
331. Ishida T, Fenselau C, Kaltashov I, Yu X Evaluation of electrospray for drug analysis. Nippon Iyo Masu Supekutoru Gakkai Koenshu 1992, 17:275-276.
332. Blay PKS, Thibault P, Thiberge N, Kiecken B, Lebrun A, Mercure C Analysis of taxol and related taxanes from Taxus canadensis using liquid chromatography combined with mass spectrometry or tandem mass spectrometry. Rapid Commun. Mass Spectrom. 1993, 7:626-634.
333. Liu J, Volk KJ, Mata MJ, Kerns EH, Lee MS Miniaturized HPLC and ionspray mass spectrometry applied to the analysis of Paclitaxel and taxanes. J. Pharm. Biomed. Anal. 1997, 15:1729-1739.
334. Gimon ME, Kinsel GR, Edmondson RD, Russell DH, Prout T, Ewald HA Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry of paclitaxel and related taxanes. J. Nat. Prod. 1994, 57:1404-1410.
335. Bitsch F, Ma W, Macdonald F, Nieder M, Shackleton CHL Analysis of taxol and related diterpenoids from cell cultures by liquid chromatography-electrospray mass spectrometry. J. Chromatogr. Biomed. Appl. 1993, 615:273-280.
336. Bitsch F, Shackleton CHL, Ma W, Park G, Nieder M Taxoid side-chain structure determination by electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 1993, 7:891-894.
337. Kerns EH, Volk KJ, Hill SE, Lee MS Profiling taxanes in Taxus extracts using LC/MS and LC/MS/MS techniques. J. Nat. Prod. 1994, 57:1391-1403.
338. Stierle A, Strobel G, Stierle D Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of Pacific yew. Science 1993, 260:214-217.
339. Stierle A, Strobel G, Stierle D, Grothaus P, Bignami G The search for a taxol-producing microorganisms among the endophytic fungi of the Pacific yew, Taxus brevifolia. J. Nat. Prod. 1995, 58:1315-1324.
340. Noh M-J, Yang J-G, Kim K-S, et al. Isolation of a novel microorganism, Pestalotia heterocornis, producing paclitaxel. Biotechnol. Bioeng. 1999, 64:620-623.
341. Han KH, Fleming P, Walker K, et al. Genetic transformation of mature Taxus: An approach to genetically control the in vitro production of the anticancer drug, taxol. Plant Sci. 1994, 95:187-196.
342. Zhiri A, Jaziri M, Guo Y, et al. Tissue cultures of Taxus baccata as a source of 10-deacetyl-baccatin III, a precursor for the hemisynthesis of taxol. Biol. Chem. Hoppe-Seyler 1995, 376:583-586.
343. Theodoridis G, Laskaris G, Van Rozendaal ELM, Verpoorte R Analysis of taxines in Taxus plant material and cell cultures by HPLC photodiode array and HPLC-electrospray mass spectrometry. J. Liq. Chromatogr. Relat. Technol. 2001, 24:2267-2282.
344. Cavaletti G, Cavalletti E, Oggioni N, et al. Distribution of paclitaxel within the nervous system of the rat after ed intravenous administration. Neurotoxicology 2000, 21:389-393.
345. Schellen A, Ooms B, Van Gils M, et al. High throughput on-line solid phase extraction/tandem mass spectrometric determination of paclitaxel in human serum. Rapid Commun. Mass Spectrom. 2000, 14:230-233.
346. Blitzke T, Baranovsky A, Schneider B Synthesis and protein binding of 4-carboxybutylcarbamoyl-substituted taxoids. Helv. Chim. Acta 2001, 84:1989-1995.
347. Xu QA, Trissel LA, Davis MR Compatibility of paclitaxel in 5% glucose and 0.9% sodium chloride injections with EVA minibags. Aust. J. Hosp. Pharm. 1998, 28:156-159.
348. Hoke SH, Cooks RG, Chang CJ, et al. Determination of taxanes in Taxus brevifolia extracts by tandem mass spectrometry and high-performance liquid chromatography. J. Nat. Prod. 1994, 57:277-286.
349. Theodoridis G, Laskaris G, de Jong CF, Hofte AJP, Verpoorte R Determination of paclitaxel and related diterpenoids in plant extracts by high-performance liquid chromatography with UV detection in high-performance liquid chromatography-mass spectrometry. J. Chromatogr. A 1998, 802:297-305.
350. Sottanil C, Minoia C, D'Incalci M, Paganini M, Zucchetti M High-performance liquid chromatography tandem mass spectrometry procedure with automated solid phase extraction sample preparation for the quantitative determination of paclitaxel (taxol) in human plasma. Rapid Commun. Mass Spectrom. 1998, 12:251-255.
351. Volk KJ, Hill SE, H Kerns E, Lee MS Profiling degradants of paclitaxel using liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry substructural techniques. J. Chromatogr. B: Biomed. Sci. Appl. 1997, 696:99-115.
352. Fleming PE, Floss HG, Haertel M, et al. Biosynthetic studies on taxol. Pure Appl. Chem. 1994, 66:2045-2048.
353. Kerns EH, Hill SE, Detlefsen DJ, et al. Cellular uptake profile of paclitaxel using liquid chromatography tandem mass spectrometry. Rapid Commun. Mass Spectrom. 1998, 12:620-624.
354. Lorenz SA, Maziarz EP, Wood TD Using solution phase hydrogen/deuterium (H/D) exchange to determine the origin of non-covalent complexes observed by electrospray ionization mass spectrometry: In solution or in vacuo. J. Am. Soc. Mass Spectrom. 2001, 12:795-804.
355. Chandra S, Lorey DR SIMS ion microscopy in cancer research: Single cell isotopic imaging for chemical composition, cytotoxicity and cell cycle recognition. Cell. Mol. Biol. 2001, 47:503-518.
356. Troendle FJ, Reddick CD, Yost RA Detection of pharmaceutical compounds in tissue by matrixassisted laser desorption/ionization and laser desorption/chemical ionization Tandem mass spectrometry with a quadruple ion trap. J. Am. Soc. Mass Spectrom. 1999, 10:1315-1321.
357. Bakhtiar R, Lohne J, Ramos L, Khemani L, Hayes M, Tse F High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. J. Chromat. B: Anal. Tech. Biomed. Life Sci. 2002, 768:325-340.
358. Rai AJ, Chan DW Cancer proteomics: New developments in clinical chemistry. Laboratoriumsmedizin 2001, 25:399-403.
359. Verma M, Wright GL, Hanash SM, Gopal-Srivastava R, Srivastava S Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers. Ann. N. Y. Acad. Sci. (Circulating Nucleic Acids in Plasma or Serum II 2001, 945:103-115.
360. Wright GL, Cazares LH, Leung S-M, et al. ProteinChip surface enhanced laser desorption/ionization (SELDI) mass spectrometry: A novel protein
361. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359:572-577.
362. Hanash S, Brichory F, Beer D A proteomic approach to the identification of lung cancer markers. Dis. Markers 2001, 17:295-300.
363. Paweletz CP, Trock B, Pennanen M, et al. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: Potential for new biomarkers to aid in the diagnosis of breast cancer. Dis. Markers 2001, 17:301-307.
364. Harris RA, Yang A, Stein RC, et al. Cluster analysis of an extensive human breast cancer cell line protein expression map database. Proteomics 2002, 2:212-223.
365. Shalhoub P, Kern S, Girard S, Beretta L Proteomic-based approach for the identification of tumor markers associated with hepatocellular carcinoma. Dis. Markers 2001, 17:217-223.
366. Barnea E, Beer I, Patoka R, et al. Analysis of endogenous peptides bound by soluble MHC class I molecules: a novel approach for identifying tumor-specific antigen. Eur. J. Immunol. 2002, 32:213-222.
367. Parish CR, Cabalda-Crane VM Method of identifying cancer markers by mass spectrometry and uses therefore in the diagnosis of cancer. PCT Int. Appl. 2002, 55.
368. Siegel MM Early discovery drug screening using mass spectrometry. Curr. Top. Med. Chem. 2002, 2:13-33.
369. Loo JA, Hu P, Thanbal V Studying noncovalent protein-peptide interactions by electrospray ionization mass spectrometry. Proceedings of the 43rd ASMS Conference on Mass Spectrometry and Allied Topics 1995, 35.
370. Loo JA Bioanalytical mass spectrometry: many flavors to choose. Bioconjugate Chem. 1995, 6:644-665.
371. Ganguly AK, Pramanik BN, Tsarbopoulos A, Covey TR, Huang E, Fuhrman SA Mass spectrometric detection of the noncovalent GDP-bound conformational state of the human H-ras protein. J. Am. Chem. Soc. 1992, 114:6559-6560.
372. Huang EC, Pramanik BN, Tsarbopoulos A, et al. Application of electrospray mass spectrometry in probing protein-protein and protein-ligand noncovalent interactions. J. Am. Soc. Mass Spectrom. 1993, 4:624-630.
373. Ganguly AK, Pramanik BN, Huang EC, Tsarbopoulos A, Girijavallabhan VM, Liberles S Studies of the ras-GDP and ras-GTP noncovalent complexes by electrospray mass spectrometry. Tetrahedron 1993, 49:7985-7996.
374. Taveras AG, Remiszewski SW, Doll RJ, et al. Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex. Bioorg. Med. Chem. 1997, 5:125-133.
375. Grieg M, Robinson J Detection of oligonucleotide ligand complexes by ESI-MS (DOLCEMS) as a component of high throughput screening. CPSA 2000 - 3rd Annual Symposium on Chemical and Pharmaceutical Structure Analysis 2000, Princeton, NJ.
376. Hofstadler SA, Griffey RH Analysis of Noncovalent Complexes of DNA and RNA by Mass Spectrometry. Chem. Rev. 2001, 101:377-390.
377. Wan KX, Shibue T, Gross ML Non-covalent complexes between DNA-binding drugs and double-stranded oligodeoxynucleotides: A study by ESI ion-trap mass spectrometry. J. Am. Chem. Soc. 2000, 122:300-307.
378. Shibue T, Wan KX, Gross ML A study of non-covalent interaction between DNA-binding drugs and double-stranded oligodeoxynucleotides by ESI ion trap mass spectrometry. J. Mass Spectrom. Soc. Jpn. 2000, 48:221-227.
379. Wan KX, Gross ML, Shibue TJ Gas-phase stability of double-stranded oligodeoxynucleotides and their noncovalent complexes with DNA-binding drugs as revealed by collisional activation in an ion trap. J. Am. Soc. Mass Spectrom. 2000, 11:450-457.
380. Gabelica V, De Pauw E, Rosu F Interaction between antitumor drugs and a double-stranded oligonucleotide studied by electrospray ionization mass spectrometry. J. Mass Spectrom. 1999, 34:1328-1337.
381. Hofstadler SA, Griffey RH Mass spectrometry as a drug discovery platform against RNA targets. Curr. Opin. Drug Disc. Dev. 2000, 3:423-431.
382. Griffey RH, Sannes-Lowery KA, Drader JJ, Mohan V, Swayze EE, Hofstadler SA Characterization of low-affinity complexes between RNA and small molecules using electrospray ionization mass spectrometry. J. Am. Chem. Soc. 2000, 122:9933-9938.
383. Fry DW, Bridges AJ, Denny WA, et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:12022-12027.
384. Smaill JB, Rewcastle GW, Loo JA, et al. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J. Med. Chem. 2000, 43:1380-1397.
385. Kelleher NL, Lin HY, Valaskovic GA, Aaserud DJ, Fridriksson EK, McLafferty FW Top down versus bottom up protein characterization by tandem high-resolution mass spectrometry. J. Am. Chem. Soc. 1999, 121:806-812.
386. Siegel MM, Tabei K, Bebernitz GA, Baum EZ Rapid methods for screening low molecular mass compounds non-covalently bound to proteins using size exclusion and mass spectrometry applied to inhibitors of human cytomegalovirus protease. J. Mass Spectrom. 1998, 33:264-273.
387. Dunayevskiy YM, Lai J-J, Quinn C, Talley F, Vouros P Mass spectrometric identification of ligands selected from combinatorial libraries using gel filtration. Rapid Commun. Mass Spectrom. 1997, 11:1178-1184.
388. Blom KF, Larsen Bs, McEwen CN Determining affinity-selected ligands and estimating binding affinities by online size exclusion chromatography/liquid chromatography-mass spectrometry. J. Comb. Chem. 1999, 1:82-90.
389. Annis A An affinity selection-mass spectral method for the identification of small molecule ligands from self-encoded combinatorial libraries 2000, Dec. 13, www.neogenesis.com., Greater Boston Mass Spectrometry Discussion Group, New York.
390. Hsieh YF, Gordon N, Regnier F, Afeyan N, Martin SA, Vella G Multidimensional chromatography coupled with mass spectrometry for target-based screening. J. Mol. Diversity 1997, 2:189-196.
391. Dunayevskiy YM, Hughes DE High throughput size-exclusive method of screening complex biological materials for affinity ligands. PCT Int. Appl. 2000, 33. WO 0047999 A1 20000817.
392. Tong H, Tabei K, Amin A, Olson M, Bebernitz G, Siegel MM Identification of compounds non-covalently bound to RNA using GPC spin columns with ESI MS. Proceedings of the 49th American Society of Mass Spectrometry Conference on Mass Spectrometry & Allied Topics 2001, Poster Th 274.
393. Moy FJ, Haraki K, Mobilio D, Walker G, Powers R, Tabei K, Tong H, Siegel MM MS/NMR: A structure-based approach for discovering protein ligands and for drug design by coupling size exclusion chromatography, mass spectrometry, and nuclear magnetic resonance spectroscopy. Anal. Chem. 2001, 73:571-581.
394. Dohlman HG, Thorner J RGS proteins and signaling by heterotrimeric G proteins. J. Biol. Chem. 1997, 272:3871-3874.
395. Kehrl JH Heterotrimeric G protein signaling: roles in immune function and fine-tuning by RGS proteins. Immunity 1998, 8:1-10.
396. Arshavsky VY, Pugh EN Lifetime regulation of G protein-effector complex: Emerging importance of RGS proteins. Neuron 1998, 20:11-14.
397. Zerangue N, Jan LY G-protein signaling: fine-tuning signaling kinetics. Curr. Biol. 1998, 8:R313-R316.
398. De Vries L, Farquhar MG RGS proteins: More than just GAPs for heterotrimeric G proteins. Trends Cell Biol. 1999, 9:138-144.
399. McLafferty FW, Turecek F Interpretation of Mass Spectra; An Introduction 1993, University Science Books.
400. Harrison AG Chemical Ionization Mass Spectrometry 1992, CRC Press, Mill Valley CA.
401. Schulten HR Biochemical, medical, and environmental applications of field-ionization and field-desorption mass spectrometry. Int. J. Mass Spectrom. Ion Phys. 1979, 32:97-283.
402. Prokai L Field Desorption Mass Spectrometry 1990, Marcel Dekker, Boca Raton, FL.
403. Sundqvist B, Macfarlane RD Californium-252-plasma desorption mass spectrometry. Mass Spectrom. Rev. 1985, 4:421-460.
404. Benninghaven A, Rudenauer FG, Werner HW Secondary Ion Mass Spectrometry 1987, Wiley-Interscience, New York.
405. Seifert WEJ, Caprioli RM Fast atom bombardment mass spectrometry. Methods Enzymol. 1996, 270:453-486.
406. Vestal ML Ionization techniques for nonvolatile molecules. Mass Spectrom. Rev. 1983, 2:447-480.
407. Niessen WMA Liquid Chromatography-Mass Spectrometry 2000, Marcel Dekker, New York.
408. Electrospray Ionization Mass Spectrometry 1997, John Wiley, New York. R.B. Cole (Ed.).
409. Applied Electrospray Mass Spectrometry 2000, Marcel Dekker, New York. B.N. Pramanik, A.K. Ganguly, M.L. Gross (Eds.).
410. Zenobi R, Knochenmuss R Ion formation in MALDI mass spectrometry. Mass Spectrom. Rev. 1999, 17:337-366.
411. Bahr U, Karas M, Hillenkamp FF Analysis of biopolymers by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry. Fresenius' J. Anal. Chem. 1994, 348:783-791.
412. Merchant M, Weinberger SR Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2000, 21:1164-1177.
413. Lasers and Mass Spectrometry 1990, Oxford University Press, New York. D.M. Lubman (Ed.).
414. Inductively Coupled Plasma Mass Spectrometry 1998, Wiley-VCH, New York. A. Montaser (Ed.).
415. Busch KL, Glish GL, McLuckey SA Mass Spectrometry/Mass Spectrometry 1988, VHC, New York.
416. Tandem Mass Spectrometry 1983, John Wiley, New York. F.W. McLafferty (Ed.).
417. Collision Spectroscopy 1978, Plenum Press, New York. R.G. Cooks (Ed.).
418. Current Practice of Gas Chromatography-Mass Spectrometry 2001, Marcel Dekker, New York. W.M.A. Niessen (Ed.).
419. Lee MS LC/MS Applications in Drug Development 2002, John Wiley, New York.
420. Combs MT, Ashraf-Khorassani M, Taylor LT Packed column supercritical fluid chromatography-mass spectroscopy: A review. J. Chromatogr. 1997, 785:85-100.
421. Cherkaoui S Combining capillary electrophoresis with electrospray ionization mass spectrometry. Clinical and Forensic Applications of Capillary Electrophoresis 2001, 285-313. Humana Press Inc., New York. J.R. Petersen, A.A. Mohammad (Eds.).
422. Hage T, Sebald W, Reinemer P Crystal structure of the interleukin-4/receptor a chain complex reveals a mosaic binding interface. Cell 1999, 97:271-281.
423. Shao D, et al. Identification of novel estrogen receptor & antagonist. J. Steroid Biochem. Mol. Biol. 2004, 88(4-5):351-360.
424. Moy F, et al. Impact of mobility on structure based drug design for MMPs. JACS 2002, 124(43):12658-12659.